Beam Therapeutics (BEAM) Operating Leases (2019 - 2026)

Beam Therapeutics (BEAM) has reported Operating Leases for 8 consecutive years, with $135.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 6.26% year-over-year to $135.8 million; the TTM figure through Mar 2026 stood at $135.8 million (down 6.26% YoY), while the FY2025 annual figure was $139.8 million, down 5.54% from the prior year.
• Operating Leases retreated to $135.8 million in Q1 2026 per BEAM's latest filing, from $139.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $168.6 million in Q4 2022 and bottomed at $135.8 million in Q1 2026.
• Historically, Operating Leases has averaged $152.4 million across 5 years, with a median of $152.6 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases climbed 25.08% — and 2024, when it declined 7.48%.
• Beam Therapeutics' Operating Leases stood at $168.6 million in 2022, then fell by 5.17% to $159.9 million in 2023, then retreated by 7.48% to $148.0 million in 2024, then slipped by 5.54% to $139.8 million in 2025, then fell by 2.8% to $135.8 million in 2026.
• Business Quant data shows BEAM's Operating Leases at $135.8 million in Q1 2026, $139.8 million in Q4 2025, and $138.7 million in Q3 2025.